- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05147727
Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects
December 22, 2022 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Single-center, Open-label, Fixed-sequence Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of Famitinib in Healthy Subjects
An open-label, fixed-sequence, drug-drug interaction study to evaluate the effects of fluconazole on the pharmacokinetics and safety of famitinib in healthy subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400010
- The Second Affiliated Hospital of Chongqing Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- With my consent and informed consent, I am willing and able to complete the study in accordance with the requirements of the experimental protocol;
- Healthy male or female aged 18-45 years (including threshold) on the date of signing the informed consent form;
- Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) in the range of 19.0-26.0 kg / m2 (including the critical value);
- Physical examination, vital signs, laboratory measurements (blood routine, blood biochemistry, urine routine test, coagulation function, etc.), 12-lead ECG, abdominal B-ultrasound, chest X-ray, etc. are normal or abnormal, but the researcher has no clinical significance according to NCI CTCAE 5.0 standard;
- Fertile subjects had no family planning and had to take acceptable contraceptive measures and no plans to donate eggs and sperm within 3 months from the date of signing informed consent to the last medication; the serum pregnancy test of fertile women within 24 hours before the first administration of the study drug should be negative.
Exclusion Criteria:
- Those who have previously suffered from primary diseases of important organs, including but not limited to neuropsychiatric, cardiovascular, digestive tract, respiratory system, urinary, endocrine, blood, immune and other diseases, which are judged by the researchers to be unsuitable for the trial;
- Subjects who have received any previous operation affecting gastrointestinal absorption;
- Subjects who had received any surgery within 6 months before screening, or planned to undergo surgery during the study period;
- Those who lost blood or donated more than 400 ml or received blood transfusion within 3 months before screening;
- HBsAg positive, HCVAb positive, HIV antibody positive, syphilis antibody positive;
- History of drug use in the past 5 years or drug abuse, or drug screening positive;
- Smoking and alcohol addict and unable to stop smoking during the test period; those with positive alcohol screening; those with positive nicotine screening;
- Subjects who have swallowing resistance or obstacle that will affect the drug absorption;
- Allergic constitution, including severe drug allergy or drug allergy history; known allergy to fluconazole and famitinib or its excipients;
- Those who have participated in other clinical trials and taken the study drug within 3 months before taking the study drug for the first time;
- Inducers or inhibitors of CYP3A4 were taken within 4 weeks before the first administration of study drug;
- Taking any prescription drug, over-the-counter drug, traditional Chinese medicine or food supplement within 2 weeks before taking the study drug for the first time;
- Ingestion of grapefruit containing products, fruit juice, food or beverage containing methylxanthine or alcohol within 48 hours before taking the study drug for the first time; taking strenuous exercise; or having other factors affecting the absorption, distribution, metabolism and excretion of drugs;
- Lactating women;
- The researchers considered that the subjects had any other factors that were not suitable for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fluconazole and Famitinib interaction
|
Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed serum concentration (Cmax) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Area under the concentration-time curve from time zero to time t (AUC0-t,) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.) for famitinib (if applicable)
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to maximum observed serum concentration (Tmax) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Time to elimination half-life (t1/2) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Apparent oral clearance (CL/F) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Apparent Volume of Distribution (Vz/F) for famitinib
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Tmax for famitinib metabolite SHR116637
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Cmax for famitinib metabolite SHR116637
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
AUC0-t, for famitinib metabolite SHR116637
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
AUC0-∞. for famitinib metabolite SHR116637(if applicable)
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
t1/2 for famitinib metabolite SHR116637
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
Time Frame: Day 1 to Day 25
|
Day 1 to Day 25
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2022
Primary Completion (Actual)
May 2, 2022
Study Completion (Actual)
May 2, 2022
Study Registration Dates
First Submitted
December 6, 2021
First Submitted That Met QC Criteria
December 6, 2021
First Posted (Actual)
December 7, 2021
Study Record Updates
Last Update Posted (Actual)
December 23, 2022
Last Update Submitted That Met QC Criteria
December 22, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluconazole
Other Study ID Numbers
- FMTN-I-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Baodong QinRecruiting
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingSolid Tumor, Adult | Refractory TumorUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
Clinical Trials on Fluconazole、Famitinib
-
Jiangsu HengRui Medicine Co., Ltd.CompletedColorectal Cancer Metastatic | Colorectal Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, ChinaSuspendedNon-Small Cell Lung Cancer (NSCLC)China
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRenal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen UniversityCompletedRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownGastrointestinal Stromal TumorChina
-
Shanghai Chest HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingHealthy SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesTerminatedGastroenteropancreatic Neuroendocrine TumorChina